middle.news
How Is Invex Therapeutics Unlocking Exenatide’s Potential in Alzheimer’s Disease?
8:19am on Wednesday 23rd of July, 2025 AEST
•
Healthcare
Read Story
How Is Invex Therapeutics Unlocking Exenatide’s Potential in Alzheimer’s Disease?
8:19am on Wednesday 23rd of July, 2025 AEST
Key Points
Expanded R&D collaboration with Tessara Therapeutics targeting Alzheimer’s disease
Renewal of orphan drug designations for Exenatide in Europe and the US
Cash reserves steady at $5.4 million with controlled operating outflows
UK subsidiary deregistration underway to reduce corporate overheads
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IXC
OPEN ARTICLE